MP021: Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the taipei veterans general hospital experience
  • 278 views,
  • 2017-12-25,
  • 上傳者: TUA秘書處,
  •  0
局部侵犯性上泌尿道泌尿上皮癌的輔助性化療:台北榮總經驗分享
劉家翔1、黃逸修1, 3、林登龍1, 3
台北榮民總醫院泌尿部1國立陽明大學醫學系泌尿學科2書田泌尿科學研究中心3
Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Taipei Veterans General Hospital experience
Chia-Hsiang Liu1, Eric Yi-Hsiu Huang1,3, Alex T. L. Lin1,3
1 Department of Urology; 2Department of Radiology,
Taipei Veterans General Hospital, Taiwan
3 Department of Urology, School of Medicine, and Shu-Tien Urological Institute,
National Yang-Ming University, Taipei, Taiwan
 
Purpose:
To describe the long-term outcome in the treatment of locally advanced upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) regarding the role of adjuvant chemotherapy.
 
Materials and Methods:
Clinical data from 93 patients who underwent RNU from 2005 to 2010 for locally advanced UTUC ( pT3N0) were analyzed.
 
Results:
We selected 102 patients and 9 were excluded due to loss of follow-up.The adjuvant chemotherapy group comprised 63 patients, and other 30 patients did not receive adjuvant chemotherapy. The median follow-up period was 34 months for non-adjuvant chemotherapy group and 31.5 months for adjuvant chemotherapy group.Bladder recurrence rate was 33.33% for the non-adjuvant chemotherapy group versus 22.22% for the adjuvant chemotherapy group.Distant metastasis rate was 23.33% for the non-adjuvant chemotherapy group versus 33.33% for the adjuvant chemotherapy group The 5-year survival rates was 30% for the non-adjuvant chemotherapy group versus 36.5% for the adjuvant chemotherapy group .Overall survival (OS) rates was 70% for the non-adjuvant chemotherapy group versus 65.07% for the adjuvant chemotherapy group . Progression free survival rate was 40% for the non-adjuvant chemotherapy group versus 42.85% for the adjuvant chemotherapy group.
 
Conclusion:
There does not appear to be a significant over bladder recurrence,distant metastasis, 5-year survival,overaall survival or progression free survival associated with adjuvant chemotherapy. Relative less data base than previous study was limitation.Prospective randomized clinical trials are necessary to verify the effect of adjuvant chemotherapy on locally advanced UTUC(pT3N0).
 
 
附件
訪客如要回應,請先 登入
    資料夾 :
    發表時間 :
    2017-12-25 14:13:47
    觀看數 :
    278
    發表人 :
    TUA秘書處
    部門 :
    台灣泌尿科醫學會
    QR Code :